Clay B. Siegall Buys 137,100 Shares of Immunome, Inc. (NASDAQ:IMNM) Stock

Immunome, Inc. (NASDAQ:IMNM) CEO Clay B. Siegall purchased 137,100 shares of the company’s stock in a transaction that occurred on Wednesday, March 26th. The stock was acquired at an average cost of $7.29 per share, with a total value of $999,459.00. Following the purchase, the chief executive officer now directly owns 806,736 shares of the company’s stock, valued at $5,881,105.44. This trade represents a 20.47 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Immunome Price Performance

Shares of NASDAQ IMNM opened at $7.28 on Friday. Immunome, Inc. has a 1 year low of $6.94 and a 1 year high of $25.75. The firm has a 50-day moving average of $9.56 and a 200 day moving average of $11.38. The stock has a market cap of $633.00 million, a P/E ratio of -0.90 and a beta of 1.93.

Immunome (NASDAQ:IMNM) last released its earnings results on Wednesday, March 19th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.16). The business had revenue of $2.74 million for the quarter, compared to analysts’ expectations of $3.07 million. Immunome had a negative net margin of 3,014.59% and a negative return on equity of 48.63%. Research analysts expect that Immunome, Inc. will post -2.21 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. grew its stake in shares of Immunome by 6.6% in the third quarter. JPMorgan Chase & Co. now owns 24,565 shares of the company’s stock worth $359,000 after acquiring an additional 1,520 shares during the last quarter. Sequoia Financial Advisors LLC increased its stake in Immunome by 11.7% during the 4th quarter. Sequoia Financial Advisors LLC now owns 19,065 shares of the company’s stock valued at $202,000 after purchasing an additional 2,000 shares in the last quarter. Wealth Enhancement Advisory Services LLC raised its holdings in Immunome by 5.1% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 41,505 shares of the company’s stock worth $441,000 after buying an additional 2,005 shares during the last quarter. Intech Investment Management LLC lifted its stake in shares of Immunome by 26.5% in the fourth quarter. Intech Investment Management LLC now owns 18,961 shares of the company’s stock worth $201,000 after buying an additional 3,974 shares in the last quarter. Finally, Wellington Management Group LLP lifted its stake in shares of Immunome by 3.5% in the fourth quarter. Wellington Management Group LLP now owns 145,564 shares of the company’s stock worth $1,546,000 after buying an additional 4,874 shares in the last quarter. Hedge funds and other institutional investors own 44.58% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. Stephens reaffirmed an “overweight” rating and issued a $30.00 target price on shares of Immunome in a research report on Thursday, March 20th. Lifesci Capital initiated coverage on shares of Immunome in a research note on Tuesday, March 11th. They issued an “outperform” rating and a $20.00 price target for the company. Guggenheim cut their price objective on Immunome from $35.00 to $25.00 and set a “buy” rating on the stock in a research report on Thursday, March 20th. Finally, Wedbush reissued an “outperform” rating and issued a $33.00 target price on shares of Immunome in a research report on Thursday, March 20th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $25.50.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.